{
	"studies": [
		{
			"protocolSection": {
				"identificationModule": {
					"nctId": "NCT00072579",
					"orgStudyIdInfo": {
						"id": "CCCWFU-23102"
					},
					"secondaryIdInfos": [
						{
							"id": "CDR0000340983",
							"type": "REGISTRY",
							"domain": "PDQ (Physician Data Query)"
						},
						{
							"id": "BRLX-02153"
						},
						{
							"id": "NCI-7350"
						}
					],
					"organization": {
						"fullName": "Wake Forest University Health Sciences",
						"class": "OTHER"
					},
					"briefTitle": "Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment",
					"officialTitle": "Phase II Study of GM-CSF in Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) Who Are Not in Complete Cytogenetic Remission After Initial Therapy"
				},
				"statusModule": {
					"statusVerifiedDate": "2013-06",
					"overallStatus": "COMPLETED",
					"expandedAccessInfo": {
						"hasExpandedAccess": false
					},
					"startDateStruct": {
						"date": "2003-05"
					},
					"primaryCompletionDateStruct": {
						"date": "2006-04",
						"type": "ACTUAL"
					},
					"completionDateStruct": {
						"date": "2007-12",
						"type": "ACTUAL"
					},
					"studyFirstSubmitDate": "2003-11-04",
					"studyFirstSubmitQcDate": "2003-11-04",
					"studyFirstPostDateStruct": {
						"date": "2003-11-05",
						"type": "ESTIMATED"
					},
					"lastUpdateSubmitDate": "2017-01-17",
					"lastUpdatePostDateStruct": {
						"date": "2017-01-19",
						"type": "ESTIMATED"
					}
				},
				"sponsorCollaboratorsModule": {
					"responsibleParty": {
						"type": "SPONSOR"
					},
					"leadSponsor": {
						"name": "Wake Forest University Health Sciences",
						"class": "OTHER"
					},
					"collaborators": [
						{
							"name": "National Cancer Institute (NCI)",
							"class": "NIH"
						}
					]
				},
				"descriptionModule": {
					"briefSummary": "RATIONALE: Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood and may bring about complete remission in patients who have chronic phase chronic myelogenous leukemia.\n\nPURPOSE: This phase II trial is studying sargramostim to see how well it works in treating patients with chronic phase chronic myelogenous leukemia that is not in complete cytogenetic remission after initial treatment.",
					"detailedDescription": "OBJECTIVES:\n\n* Determine the efficacy and safety of sargramostim (GM-CSF) by cytogenetic examination of the bone marrow in patients with chronic phase chronic myelogenous leukemia who are not in complete cytogenetic remission after initial therapy.\n\nOUTLINE: Patients receive sargramostim (GM-CSF) subcutaneously daily for 3 months in the absence of disease progression or unacceptable toxicity. Patients achieving no response receive GM-CSF for an additional 3 months. Patients failing to achieve a partial response or better after the second course of GM-CSF are removed from the study. Patients achieving a partial response after the first or second course of GM-CSF continue to receive GM-CSF for an additional 9 months. Patients are then re-evaluated. Patients achieving a complete cytologic response at 9 months then receive GM-CSF 3 times weekly in the absence of disease progression or unacceptable toxicity.\n\nPatients are followed every 2 weeks.\n\nPROJECTED ACCRUAL: A total of 9-24 patients will be accrued for this study within 3 years."
				},
				"conditionsModule": {
					"conditions": [
						"Leukemia"
					],
					"keywords": [
						"chronic phase chronic myelogenous leukemia",
						"chronic myelogenous leukemia, BCR-ABL1 positive"
					]
				},
				"designModule": {
					"studyType": "INTERVENTIONAL",
					"phases": [
						"PHASE2"
					],
					"designInfo": {
						"primaryPurpose": "TREATMENT",
						"maskingInfo": {
							"masking": "NONE"
						}
					}
				},
				"armsInterventionsModule": {
					"interventions": [
						{
							"type": "BIOLOGICAL",
							"name": "sargramostim"
						}
					]
				},
				"outcomesModule": {
					"primaryOutcomes": [
						{
							"measure": "Cytogenetic response (complete and partial)"
						}
					],
					"secondaryOutcomes": [
						{
							"measure": "Toxicity as assessed by the Expanded Common Toxicity Criteria v2.0"
						},
						{
							"measure": "Time to progression"
						},
						{
							"measure": "Survival"
						}
					]
				},
				"eligibilityModule": {
					"eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed chronic phase chronic myelogenous leukemia (CML)\n\n  * Presence of t(9;22)(q34;q11) with at least 20 cells examined in metaphase by cytogenetic examination of the bone marrow\n* Complete hematologic remission during prior therapy\\* as seen on 2 separate blood count analyses, defined by the following:\n\n  * WBC no greater than 10,000/mm\\^3 AND platelet count no greater than 450,000/mm\\^3\n  * Disappearance of all signs and symptoms of disease, including palpable splenomegaly\n  * Normal differential counts (i.e., absence of blasts, promyelocytes, myelocytes, and metamyelocytes) NOTE: \\*Continuation of therapy that led to complete hematologic remission is required during study participation\n* Persistent cytogenetic disease despite 12 months of prior imatinib mesylate therapy, which may have included a trial dose-escalation OR intolerant of imatinib mesylate at a dose greater than 400 mg/day\n* Not in complete cytogenetic remission within 30 days of study entry\n\n  * Persistent Philadelphia chromosome by bone marrow exam\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* More than 6 months\n\nHematopoietic\n\n* See Disease Characteristics\n\nHepatic\n\n* Not specified\n\nRenal\n\n* Not specified\n\nOther\n\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* No uncontrolled active infective\n* No serious medical or psychiatric illness that would prevent giving informed consent or limit survival to less than 6 months\n* No other malignancy not in remission except curatively treated basal cell skin cancer or carcinoma in situ of the cervix\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Prior sargramostim (GM-CSF) allowed\n* Prior interferon alfa for CML allowed\n* No prior stem cell transplantation\n* Concurrent interferon alfa\\* for CML allowed NOTE: \\*No dose increase during study participation\n\nChemotherapy\n\n* At least 4 weeks since prior chemotherapy\n\nEndocrine therapy\n\n* Not specified\n\nRadiotherapy\n\n* At least 4 weeks since prior radiotherapy\n* No concurrent radiotherapy\n\nSurgery\n\n* At least 4 weeks since prior surgery\n\nOther\n\n* Prior imatinib mesylate for CML allowed\n* No other concurrent medication for CML\n* Concurrent imatinib mesylate\\* for CML allowed NOTE: \\*No dose increase during study participation",
					"healthyVolunteers": false,
					"sex": "ALL",
					"minimumAge": "18 Years",
					"maximumAge": "120 Years",
					"stdAges": [
						"ADULT",
						"OLDER_ADULT"
					]
				},
				"contactsLocationsModule": {
					"overallOfficials": [
						{
							"name": "Istvan Molnar, MD",
							"affiliation": "Wake Forest University Health Sciences",
							"role": "STUDY_CHAIR"
						},
						{
							"name": "Bayard L. Powell, MD",
							"affiliation": "Wake Forest University Health Sciences"
						}
					],
					"locations": [
						{
							"facility": "CCOP - Western Regional, Arizona",
							"city": "Phoenix",
							"state": "Arizona",
							"zip": "85006-2726",
							"country": "United States",
							"geoPoint": {
								"lat": 33.44838,
								"lon": -112.07404
							}
						},
						{
							"facility": "CCOP - Bay Area Tumor Institute",
							"city": "Oakland",
							"state": "California",
							"zip": "94609-3305",
							"country": "United States",
							"geoPoint": {
								"lat": 37.80437,
								"lon": -122.2708
							}
						},
						{
							"facility": "CCOP - Mount Sinai Medical Center",
							"city": "Miami Beach",
							"state": "Florida",
							"zip": "33140",
							"country": "United States",
							"geoPoint": {
								"lat": 25.79065,
								"lon": -80.13005
							}
						},
						{
							"facility": "Regional Radiation Oncology Center at Rome",
							"city": "Rome",
							"state": "Georgia",
							"zip": "30165",
							"country": "United States",
							"geoPoint": {
								"lat": 34.25704,
								"lon": -85.16467
							}
						},
						{
							"facility": "CCOP - Central Illinois",
							"city": "Decatur",
							"state": "Illinois",
							"zip": "62526",
							"country": "United States",
							"geoPoint": {
								"lat": 39.84031,
								"lon": -88.9548
							}
						},
						{
							"facility": "Kentuckiana Cancer Institute, PLLC",
							"city": "Louisville",
							"state": "Kentucky",
							"zip": "40202",
							"country": "United States",
							"geoPoint": {
								"lat": 38.25424,
								"lon": -85.75941
							}
						},
						{
							"facility": "MBCCOP - LSU Health Sciences Center",
							"city": "New Orleans",
							"state": "Louisiana",
							"zip": "70112",
							"country": "United States",
							"geoPoint": {
								"lat": 29.95465,
								"lon": -90.07507
							}
						},
						{
							"facility": "Alamance Cancer Center",
							"city": "Burlington",
							"state": "North Carolina",
							"zip": "27216",
							"country": "United States",
							"geoPoint": {
								"lat": 36.09569,
								"lon": -79.4378
							}
						},
						{
							"facility": "Hugh Chatham Memorial Hospital",
							"city": "Elkin",
							"state": "North Carolina",
							"zip": "28621",
							"country": "United States",
							"geoPoint": {
								"lat": 36.2443,
								"lon": -80.8484
							}
						},
						{
							"facility": "Southeastern Medical Oncology Center",
							"city": "Goldsboro",
							"state": "North Carolina",
							"zip": "27534-9479",
							"country": "United States",
							"geoPoint": {
								"lat": 35.38488,
								"lon": -77.99277
							}
						},
						{
							"facility": "Brody School of Medicine at East Carolina University",
							"city": "Greenville",
							"state": "North Carolina",
							"zip": "27858",
							"country": "United States",
							"geoPoint": {
								"lat": 35.61266,
								"lon": -77.36635
							}
						},
						{
							"facility": "Comprehensive Cancer Center at Wake Forest University",
							"city": "Winston-Salem",
							"state": "North Carolina",
							"zip": "27157-1096",
							"country": "United States",
							"geoPoint": {
								"lat": 36.09986,
								"lon": -80.24422
							}
						},
						{
							"facility": "CCOP - Columbus",
							"city": "Columbus",
							"state": "Ohio",
							"zip": "43206",
							"country": "United States",
							"geoPoint": {
								"lat": 39.96118,
								"lon": -82.99879
							}
						},
						{
							"facility": "Cancer Centers of the Carolinas - Eastside",
							"city": "Greenville",
							"state": "South Carolina",
							"zip": "29615",
							"country": "United States",
							"geoPoint": {
								"lat": 34.85262,
								"lon": -82.39401
							}
						},
						{
							"facility": "CCOP - Upstate Carolina",
							"city": "Spartanburg",
							"state": "South Carolina",
							"zip": "29303",
							"country": "United States",
							"geoPoint": {
								"lat": 34.94957,
								"lon": -81.93205
							}
						}
					]
				}
			},
			"derivedSection": {
				"miscInfoModule": {
					"versionHolder": "2025-05-09"
				},
				"conditionBrowseModule": {
					"meshes": [
						{
							"id": "D007938",
							"term": "Leukemia"
						},
						{
							"id": "D007951",
							"term": "Leukemia, Myeloid"
						},
						{
							"id": "D015464",
							"term": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
						},
						{
							"id": "D015466",
							"term": "Leukemia, Myeloid, Chronic-Phase"
						}
					],
					"ancestors": [
						{
							"id": "D009370",
							"term": "Neoplasms by Histologic Type"
						},
						{
							"id": "D009369",
							"term": "Neoplasms"
						},
						{
							"id": "D006402",
							"term": "Hematologic Diseases"
						},
						{
							"id": "D009196",
							"term": "Myeloproliferative Disorders"
						},
						{
							"id": "D001855",
							"term": "Bone Marrow Diseases"
						},
						{
							"id": "D002908",
							"term": "Chronic Disease"
						},
						{
							"id": "D020969",
							"term": "Disease Attributes"
						},
						{
							"id": "D010335",
							"term": "Pathologic Processes"
						}
					],
					"browseLeaves": [
						{
							"id": "M10945",
							"name": "Leukemia",
							"asFound": "Leukemia",
							"relevance": "HIGH"
						},
						{
							"id": "M10955",
							"name": "Leukemia, Myeloid",
							"asFound": "Myelogenous Leukemia",
							"relevance": "HIGH"
						},
						{
							"id": "M18123",
							"name": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
							"asFound": "Chronic myelogenous leukemia",
							"relevance": "HIGH"
						},
						{
							"id": "M18125",
							"name": "Leukemia, Myeloid, Chronic-Phase",
							"asFound": "Chronic phase chronic myelogenous leukemia",
							"relevance": "HIGH"
						},
						{
							"id": "M12315",
							"name": "Neoplasms by Histologic Type",
							"relevance": "LOW"
						},
						{
							"id": "M9490",
							"name": "Hematologic Diseases",
							"relevance": "LOW"
						},
						{
							"id": "M12149",
							"name": "Myeloproliferative Disorders",
							"relevance": "LOW"
						},
						{
							"id": "M5134",
							"name": "Bone Marrow Diseases",
							"relevance": "LOW"
						},
						{
							"id": "M6147",
							"name": "Chronic Disease",
							"relevance": "LOW"
						},
						{
							"id": "M22700",
							"name": "Disease Attributes",
							"relevance": "LOW"
						},
						{
							"id": "T1303",
							"name": "Chronic Graft Versus Host Disease",
							"relevance": "LOW"
						},
						{
							"id": "T3995",
							"name": "Myeloid Leukemia",
							"relevance": "LOW"
						},
						{
							"id": "T1309",
							"name": "Chronic Myeloid Leukemia",
							"asFound": "Chronic myelogenous leukemia",
							"relevance": "HIGH"
						},
						{
							"id": "T1311",
							"name": "Chronic Myeloproliferative Disorders",
							"relevance": "LOW"
						}
					],
					"browseBranches": [
						{
							"abbrev": "BC04",
							"name": "Neoplasms"
						},
						{
							"abbrev": "BC15",
							"name": "Blood and Lymph Conditions"
						},
						{
							"abbrev": "All",
							"name": "All Conditions"
						},
						{
							"abbrev": "BC23",
							"name": "Symptoms and General Pathology"
						},
						{
							"abbrev": "Rare",
							"name": "Rare Diseases"
						}
					]
				},
				"interventionBrowseModule": {
					"meshes": [
						{
							"id": "C081222",
							"term": "Sargramostim"
						}
					],
					"ancestors": [
						{
							"id": "D007155",
							"term": "Immunologic Factors"
						},
						{
							"id": "D045505",
							"term": "Physiological Effects of Drugs"
						}
					],
					"browseLeaves": [
						{
							"id": "M257633",
							"name": "Molgramostim",
							"relevance": "LOW"
						},
						{
							"id": "M219218",
							"name": "Sargramostim",
							"asFound": "Perioperative",
							"relevance": "HIGH"
						},
						{
							"id": "M10201",
							"name": "Immunologic Factors",
							"relevance": "LOW"
						}
					],
					"browseBranches": [
						{
							"abbrev": "ANeo",
							"name": "Antineoplastic Agents"
						},
						{
							"abbrev": "All",
							"name": "All Drugs and Chemicals"
						}
					]
				}
			},
			"hasResults": false
		},
		{
			"protocolSection": {
				"identificationModule": {
					"nctId": "NCT00517179",
					"orgStudyIdInfo": {
						"id": "CRE-2006.017-T"
					},
					"secondaryIdInfos": [
						{
							"id": "HARECCTR0500057"
						}
					],
					"organization": {
						"fullName": "Hospital Authority, Hong Kong",
						"class": "OTHER_GOV"
					},
					"briefTitle": "Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS",
					"officialTitle": "Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS for the Treatment of Benign Prostatic Hyperplasia"
				},
				"statusModule": {
					"statusVerifiedDate": "2011-06",
					"overallStatus": "COMPLETED",
					"expandedAccessInfo": {
						"hasExpandedAccess": false
					},
					"startDateStruct": {
						"date": "2006-04"
					},
					"completionDateStruct": {
						"date": "2007-05",
						"type": "ACTUAL"
					},
					"studyFirstSubmitDate": "2007-08-15",
					"studyFirstSubmitQcDate": "2007-08-15",
					"studyFirstPostDateStruct": {
						"date": "2007-08-16",
						"type": "ESTIMATED"
					},
					"lastUpdateSubmitDate": "2011-06-14",
					"lastUpdatePostDateStruct": {
						"date": "2011-06-16",
						"type": "ESTIMATED"
					}
				},
				"sponsorCollaboratorsModule": {
					"leadSponsor": {
						"name": "Hospital Authority, Hong Kong",
						"class": "OTHER_GOV"
					}
				},
				"descriptionModule": {
					"briefSummary": "The purpose of this study is to investigate the interaction between doxazosin GITS and vardenafil on blood pressure (Both systolic and diastolic blood pressure) in patients with both ED and BPH."
				},
				"conditionsModule": {
					"conditions": [
						"Prostatic Hyperplasia",
						"Impotence"
					],
					"keywords": [
						"Benign Prostatic Hyperplasia (BPH)",
						"Erectile Dysfunction (ED)"
					]
				},
				"designModule": {
					"studyType": "INTERVENTIONAL",
					"phases": [
						"NA"
					],
					"designInfo": {
						"allocation": "RANDOMIZED",
						"interventionModel": "CROSSOVER",
						"primaryPurpose": "TREATMENT",
						"maskingInfo": {
							"masking": "DOUBLE"
						}
					},
					"enrollmentInfo": {
						"count": 40,
						"type": "ESTIMATED"
					}
				},
				"armsInterventionsModule": {
					"interventions": [
						{
							"type": "DRUG",
							"name": "Vardenafil 10mg"
						}
					]
				},
				"outcomesModule": {
					"primaryOutcomes": [
						{
							"measure": "Mean maximal change of the standing systolic blood pressure (SBP) from half hour prior to till six hour after administration of the drug (baseline) with vardenafil administration versus placebo",
							"timeFrame": "From half hour prior to till six hour after administration of the drug (baseline)"
						}
					],
					"secondaryOutcomes": [
						{
							"measure": "Mean maximal post-baseline change of the standing and supine diastolic blood pressure (DBP)",
							"timeFrame": "From half hour prior to till six hour after administration of the drug (baseline)"
						},
						{
							"measure": "Mean maximal post-baseline change supine SBP, and (3) the pattern of changes of the SBP and DBP from half hour prior to till six hours after administration of the drug",
							"timeFrame": "From half hour prior to till six hour after administration of the drug (baseline)"
						}
					]
				},
				"eligibilityModule": {
					"eligibilityCriteria": "Inclusion Criteria:\n\n* Age between 50 to 80 years old\n* Clinically diagnosed to have lower urinary tract symptoms secondary to BPH:\n\n  1. Suffered from lower urinary tract symptoms with International Prostate Symptom Score (IPSS) \\>=8\n  2. Detectable prostatic enlargement determined by Digital Rectum Examination (DRE)\n  3. Urinary flow between 5 to 15ml/second in a total void volume \\>=150mL\n* Currently on regular doxazosin GITS once-daily for at least 4 weeks without clinically significant side effects\n* Complaints of erectile dysfunction with Erectile Function domain (EF) of the International Index of Erectile Function (IIEF) score \\<= 21\n\nExclusion Criteria:\n\n* Congestive heart failure, unstable angina, arrhythmia, myocardial infraction\n* Hypertension or on any antihypertensive agents\n* Take nitrate and medication contradicted to vardenafil\n* Uncontrolled or poorly controlled diabetes mellitus\n* Intolerance or contra-indicated for the use of vardenafil\n* Hepatic disorder",
					"sex": "MALE",
					"minimumAge": "50 Years",
					"maximumAge": "80 Years",
					"stdAges": [
						"ADULT",
						"OLDER_ADULT"
					]
				},
				"contactsLocationsModule": {
					"overallOfficials": [
						{
							"name": "Chi Fai Ng, Dr",
							"affiliation": "Department of Surgery, Division of Urology, The Chinese University of Hong Kong",
							"role": "PRINCIPAL_INVESTIGATOR"
						}
					],
					"locations": [
						{
							"facility": "Prince of Wales Hospital",
							"city": "Hong Kong",
							"country": "China",
							"geoPoint": {
								"lat": 22.39407,
								"lon": 114.13737
							}
						}
					]
				}
			},
			"derivedSection": {
				"miscInfoModule": {
					"versionHolder": "2025-05-09"
				},
				"conditionBrowseModule": {
					"meshes": [
						{
							"id": "D007172",
							"term": "Erectile Dysfunction"
						},
						{
							"id": "D011470",
							"term": "Prostatic Hyperplasia"
						},
						{
							"id": "D006965",
							"term": "Hyperplasia"
						}
					],
					"ancestors": [
						{
							"id": "D010335",
							"term": "Pathologic Processes"
						},
						{
							"id": "D005832",
							"term": "Genital Diseases, Male"
						},
						{
							"id": "D000091662",
							"term": "Genital Diseases"
						},
						{
							"id": "D000091642",
							"term": "Urogenital Diseases"
						},
						{
							"id": "D012735",
							"term": "Sexual Dysfunction, Physiological"
						},
						{
							"id": "D052801",
							"term": "Male Urogenital Diseases"
						},
						{
							"id": "D020018",
							"term": "Sexual Dysfunctions, Psychological"
						},
						{
							"id": "D001523",
							"term": "Mental Disorders"
						},
						{
							"id": "D011469",
							"term": "Prostatic Diseases"
						}
					],
					"browseLeaves": [
						{
							"id": "M10217",
							"name": "Erectile Dysfunction",
							"asFound": "Erectile Dysfunction",
							"relevance": "HIGH"
						},
						{
							"id": "M10016",
							"name": "Hyperplasia",
							"asFound": "Hyperplasia",
							"relevance": "HIGH"
						},
						{
							"id": "M14334",
							"name": "Prostatic Hyperplasia",
							"asFound": "Prostatic Hyperplasia",
							"relevance": "HIGH"
						},
						{
							"id": "M2876",
							"name": "Genital Diseases",
							"relevance": "LOW"
						},
						{
							"id": "M8944",
							"name": "Genital Diseases, Male",
							"relevance": "LOW"
						},
						{
							"id": "M2875",
							"name": "Urogenital Diseases",
							"relevance": "LOW"
						},
						{
							"id": "M15546",
							"name": "Sexual Dysfunction, Physiological",
							"relevance": "LOW"
						},
						{
							"id": "M27095",
							"name": "Male Urogenital Diseases",
							"relevance": "LOW"
						},
						{
							"id": "M21873",
							"name": "Sexual Dysfunctions, Psychological",
							"relevance": "LOW"
						},
						{
							"id": "M4815",
							"name": "Mental Disorders",
							"relevance": "LOW"
						},
						{
							"id": "M14473",
							"name": "Psychotic Disorders",
							"relevance": "LOW"
						},
						{
							"id": "M14333",
							"name": "Prostatic Diseases",
							"relevance": "LOW"
						}
					],
					"browseBranches": [
						{
							"abbrev": "BXS",
							"name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
						},
						{
							"abbrev": "BXM",
							"name": "Behaviors and Mental Disorders"
						},
						{
							"abbrev": "All",
							"name": "All Conditions"
						},
						{
							"abbrev": "BC23",
							"name": "Symptoms and General Pathology"
						}
					]
				},
				"interventionBrowseModule": {
					"meshes": [
						{
							"id": "D000069058",
							"term": "Vardenafil Dihydrochloride"
						}
					],
					"ancestors": [
						{
							"id": "D014665",
							"term": "Vasodilator Agents"
						},
						{
							"id": "D058986",
							"term": "Phosphodiesterase 5 Inhibitors"
						},
						{
							"id": "D010726",
							"term": "Phosphodiesterase Inhibitors"
						},
						{
							"id": "D004791",
							"term": "Enzyme Inhibitors"
						},
						{
							"id": "D045504",
							"term": "Molecular Mechanisms of Pharmacological Action"
						},
						{
							"id": "D064804",
							"term": "Urological Agents"
						}
					],
					"browseLeaves": [
						{
							"id": "M19586",
							"name": "Doxazosin",
							"relevance": "LOW"
						},
						{
							"id": "M350",
							"name": "Vardenafil Dihydrochloride",
							"asFound": "VP-16",
							"relevance": "HIGH"
						},
						{
							"id": "M17412",
							"name": "Vasodilator Agents",
							"relevance": "LOW"
						},
						{
							"id": "M29332",
							"name": "Phosphodiesterase 5 Inhibitors",
							"relevance": "LOW"
						},
						{
							"id": "M13629",
							"name": "Phosphodiesterase Inhibitors",
							"relevance": "LOW"
						},
						{
							"id": "M7951",
							"name": "Enzyme Inhibitors",
							"relevance": "LOW"
						}
					],
					"browseBranches": [
						{
							"abbrev": "AnAg",
							"name": "Antihypertensive Agents"
						},
						{
							"abbrev": "All",
							"name": "All Drugs and Chemicals"
						},
						{
							"abbrev": "VaDiAg",
							"name": "Vasodilator Agents"
						},
						{
							"abbrev": "Urol",
							"name": "Urological Agents"
						}
					]
				}
			},
			"hasResults": false
		}
	]
}